Since HK1 knockdown induces tumor malignancy via deregulation of energetic metabolism from aerobic respiration to glycolysis, the commonly used glycolytic inhibitor 2-DG is thus a potential chemotherapeutic agent for HK1-silenced cells. This evidence concerns the gene HK1 and neoplasm.